NEW YORK, March 10, 2014 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") today announced it has submitted a Marketing Authorization Application ("MAA") to the European Medicines Agency ("EMA"), seeking the approval of Zerenex™ (ferric citrate coordination complex) as a treatment for hyperphosphatemia in patients with chronic kidney disease ("CKD"), including dialysis- and non-dialysis dependent CKD.
Help employers find you! Check out all the jobs and post your resume.
